Print

Lantheus Medical Imaging Announces FDA Approval of Jubilant HollisterStier as a New Manufacturing Site for DEFINITY®  
2/11/2013 10:00:50 AM

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of a Supplemental New Drug Application (sNDA) that allows Jubilant HollisterStier (JHS) to be a new manufacturing site for its ultrasound imaging agent DEFINITY® Vial for (Perflutren Liquid Microsphere) Injectable Suspension.1 DEFINITY® is an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.1
//-->